Business Standard

Page 3 - Astrazeneca

Australia drugs regulator approves India-made AstraZeneca vaccine for Covid

China-made vaccine recognised as well as Australia starts to unwind some of the world's most intense pandemic border restrictions.

Australia drugs regulator approves India-made AstraZeneca vaccine for Covid
Updated On : 01 Oct 2021 | 9:47 AM IST

AstraZeneca to seek US approval for Covid-19 vaccine later this year

The pharmaceutical company AstraZeneca will file a request for approval of its novel coronavirus vaccine in the US later this year, the company said in a statement

AstraZeneca to seek US approval for Covid-19 vaccine later this year
Updated On : 30 Sep 2021 | 8:30 AM IST

New AstraZeneca tie-up to explore vaccine tech for cancer, heart disease

An Imperial College London start-up has tied up with British-Swedish biopharmaceutical major AstraZeneca to explore the therapeutic uses of its vaccine technology

New AstraZeneca tie-up to explore vaccine tech for cancer, heart disease
Updated On : 28 Sep 2021 | 10:08 PM IST

AstraZeneca Pharma India gets nod to import, market Selumetinib capsules

Drug firm AstraZeneca Pharma India on Sunday said it has received import and market permission from the Indian drug regulator for Selumetinib capsules. The company has received the import and market permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsules, AstraZeneca Pharma India said in a regulatory filing. The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsules in India, subject to the receipt of related statutory approvals and licenses, it added. Selumetinib 10 mg & 25 mg capsules are indicated for treatment of pediatric patients 3 years of age and older with neurofibromatosis type 1 and who have symptomatic, inoperable plexiform neurofibromas, it added.

AstraZeneca Pharma India gets nod to import, market Selumetinib capsules
Updated On : 26 Sep 2021 | 11:07 PM IST

Covid-19 vaccine: AstraZeneca to develop Imperial's new RNA technology

Under the deal, VaxEquity, a start-up founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met

Covid-19 vaccine: AstraZeneca to develop Imperial's new RNA technology
Updated On : 23 Sep 2021 | 10:43 PM IST

Not many places left for Covid to evade immunity: UK vaccine creator

There aren't many places left for the COVID-19 virus to mutate and evade immunity as it will only get weaker with time, said the creator of the Oxford-AstraZeneca vaccine

Not many places left for Covid to evade immunity: UK vaccine creator
Updated On : 23 Sep 2021 | 10:34 PM IST

India may allow smaller gap between Covishield doses sold privately: Report

Private hospitals and clinics will give their paying patients the option to receive their second dose of the vaccine 4 weeks after the first, down from between 12 and 16 weeks currently, say sources

India may allow smaller gap between Covishield doses sold privately: Report
Updated On : 22 Sep 2021 | 2:14 PM IST
Updated On : 22 Sep 2021 | 12:38 PM IST

EU says people vaccinated with AstraZeneca should be able to travel to US

The EU has its own safe-travel list, from which the United States was recently removed after a spike in infections there.

EU says people vaccinated with AstraZeneca should be able to travel to US
Updated On : 21 Sep 2021 | 7:31 PM IST

UK approves Pfizer, AstraZeneca vaccines as booster doses for Covid-19

The UK's health regulator has approved Pfizer and AstraZeneca vaccines for booster doses against Covid-19, even as the country's decision on the third dose remains pending.

UK approves Pfizer, AstraZeneca vaccines as booster doses for Covid-19
Updated On : 10 Sep 2021 | 3:16 PM IST

Astrazeneca and European Union strike deal to end vaccine supply dispute

The deal ends a blame game over the EU's slow start in vaccinating its 448 million population

Astrazeneca and European Union strike deal to end vaccine supply dispute
Updated On : 03 Sep 2021 | 5:24 PM IST

Better than booster shots, non-vaccines promise to build Covid immunity

Monoclonal antibodies boost immune response to infections by binding to particular sites on the spike protein of the virus that causes Covid-19.

Better than booster shots, non-vaccines promise to build Covid immunity
Updated On : 27 Aug 2021 | 1:04 PM IST

No plan yet to revise Covishield 84-day dose gap, clarifies govt

Earlier there were reports that government could make a move to reduce the minimum gap between two doses of the Covishield Covid-19 vaccine, but NTAGI has denied the reports

No plan yet to revise Covishield 84-day dose gap, clarifies govt
Updated On : 26 Aug 2021 | 8:26 PM IST

SII informs Centre it will supply around 200 mn Covishield doses in Sep

SII has informed the Centre that it will be able to supply around 20 crore doses of COVID-19 vaccine Covishield in September itself to Government to India and private hospitals, official sources said

SII informs Centre it will supply around 200 mn Covishield doses in Sep
Updated On : 26 Aug 2021 | 5:39 PM IST

India to resume Covid vaccine exports in 2022: Head of govt expert panel

A second wave of Covil infections and local supply delays prompted the government to prioritize its own citizens and halted overseas shipments of vaccines in April.

India to resume Covid vaccine exports in 2022: Head of govt expert panel
Updated On : 24 Aug 2021 | 1:24 PM IST

Astrazeneca-Sputnik jabs in combo show a better immune response: RDIF

Preliminary results from Azerbaijan trials have been announced

Astrazeneca-Sputnik jabs in combo show a better immune response: RDIF
Updated On : 21 Aug 2021 | 1:58 AM IST

AstraZeneca's antibody drug prevents Covid-19 in high-risk groups

Results from Astra's study found no one in the trial who received the cocktail contracted severe Covid-19 or died in relation to the disease, the company said in a statement Friday

AstraZeneca's antibody drug prevents Covid-19 in high-risk groups
Updated On : 20 Aug 2021 | 2:36 PM IST

Pfizer and Astra vaccines less effective after 90 days, says study

The Oxford University study found that 90 days after a second shot of the Pfizer or Astra vaccine, their efficacy in preventing infections had slipped to 75 per cent and 61 per cent, respectively

Pfizer and Astra vaccines less effective after 90 days, says study
Updated On : 19 Aug 2021 | 11:46 PM IST

Pfizer, AstraZeneca vaccines less effective against Delta variant: Study

The COVID vaccines by Pfizer and AstraZeneca are less effective against the Delta variant compared to the Alpha variant, according to a study led by researchers at the University of Oxford

Pfizer, AstraZeneca vaccines less effective against Delta variant: Study
Updated On : 19 Aug 2021 | 2:35 PM IST

AstraZeneca Pharma India Q1 net profit declines 45% to Rs 10.24 cr

Drug firm AstraZeneca Pharma India on Monday reported a 45.03 per cent decline in its net profit to Rs 10.24 crore for the June ended quarter

AstraZeneca Pharma India Q1 net profit declines 45% to Rs 10.24 cr
Updated On : 09 Aug 2021 | 4:33 PM IST